Lucentis shortcuts NICE procedure in myopic CNV
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has issued final draft guidance recommending Novartis' VEGF-A inhibitor Lucentis (ranibizumab) as a treatment for visual impairment due to choroidal neovascularization secondary to pathological myopia.